GlassScriptPhysician profile
Fuad Afzal
NPI 1033195839
$1,565.16
in general payments reported to CMS, 2019-2025
22 companies · $557 in 2025
The $557 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.64 · 2020: $49.00 · 2021: $134 · 2022: $241 · 2023: $264 · 2024: $230 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $934 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $933.51 |
| Education | $117.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $271.43 | 2021-2025 | Acthar, Terlivaz |
| Otsuka America Pharmaceutical, INC. | $169.20 | 2019-2025 | Jynarque |
| Amgen INC. | $131.42 | 2019-2025 | Krystexxa |
| Aurinia Pharma U.S., INC. | $109.59 | 2021-2025 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $97.16 | 2019-2025 | Farxiga |
| Vifor Pharma, INC. | $96.86 | 2022-2023 | Veltassa |
| Travere Therapeutics, INC. | $81.96 | 2022-2025 | Filspari |
| Ardelyx, INC. | $77.78 | 2024-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $77.59 | 2022-2024 | Benlysta, Jesduvroq |
| Horizon Therapeutics Plc | $73.05 | 2020-2023 | Krystexxa |
| Fresenius USA Marketing, INC. | $54.46 | 2022-2024 | Velphoro |
| Ani Pharmaceuticals, INC. | $47.34 | 2023 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.04 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $43.27 | 2025 | |
| Novartis Pharmaceuticals Corporation | $29.96 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $28.74 | 2022 | |
| Opko Pharmaceuticals, LLC | $25.41 | 2023 | Rayaldee |
| Kyowa Kirin, INC. | $25.36 | 2023 | Crysvita |
| Ultragenyx Pharmaceutical INC. | $24.10 | 2021 | |
| Shire North American Group INC | $19.75 | 2019 | |
| Genzyme Corporation | $18.81 | 2023 | |
| Shield Therapeutics INC | $14.88 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fuad Afzal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.